SciClone is developing a portfolio of product candidates for development and commercialization in the major pharmaceutical markets and China.

For the U.S. and European pharmaceutical markets, we plan to develop our lead product thymalfasin (ZADAXIN^®) in a phase 3 malignant melanoma clinical trial. For SCV-07, we are conducting a phase 2 trial in oral mucositis and a phase 2b hepatitis C clinical trial. For RP101, we completed enrollment in our phase 2 pancreatic cancer clinical trial in the first half of 2009 and expect to report data in the first half of 2010.  In China, we are pursuing regulatory approval for DC Bead™ as an embolic agent for the treatment of liver cancer. 

Click on the image below to enlarge it